Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?

Rheumatology (United Kingdom)

Volumn 53, Issue 6, 2014, Pages 975-987

  Cappelli, Susanna ^a   Bellando randone, Silvia ^a   Guiducci, Serena ^a   Matucci cerinic, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Azathioprine; Cyclophosphamide; Hematopoietic stem cell transplantation; Methotrexate; Mycophenolate mofetil; Rituximab; Systemic sclerosis

Indexed keywords

ABATACEPT; ALEFACEPT; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TOCILIZUMAB;

CLINICAL EVALUATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL SERVICE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INTERSTITIAL LUNG DISEASE; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; REMISSION; REVIEW; SYSTEMIC SCLEROSIS; TARGET CELL;

AZATHIOPRINE; BIOLOGICAL PRODUCTS; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MYCOPHENOLIC ACID; REMISSION INDUCTION; SCLERODERMA, SYSTEMIC;

EID: 84900811420     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket312     Document Type: Review

References (96)

1. Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy 2010;2:863-78.
2. Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 2010;24:387-400.
3. Kowal-Bielecka O, Landewé R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
4. Walker KM, Pope J. Participating members of the Scleroderma Clinical Trials Consortium (SCTC), Canadian Scleroderma Research Group (CSRG). Treatment of systemic sclerosis complications: what to use when first-line treatment fails-a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012; 42:42-55.
5. van den Hoogen FH, Boerbooms AM, Swaak AJ et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72.
6. Pope JE, Bellamy N, Seibold JR et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
7. Marder W, McCune WJ. Advances in immunosuppressive therapy. Semin Respir Crit Care Med 2007;28:398-417.
8. Guillevin L, Cordier JF, Lhote F et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40: 2187-98.
9. Giacomelli R, Valentini G, Salsano F et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;29: 731-6.
10. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
11. Tashkin DP, Elashoff R, Clements PJ et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;76:1026-34.
12. Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70.
13. Nadashkevich O, Davis P, Fritzler M et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheum 2006; 25:205-12.
14. Nannini C, West CP, Erwin PJ et al. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008;10:R124.
15. Tehlirian CV, Hummers LK, White B et al. High-dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis 2008;67:775-81.
16. Johnson SR, Feldman BM, Pope JE et al. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol 2009;36: 323-9.
17. Vanthuyne M, Blockmans D, Westhovens R et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007;25:287-92.
18. Derk CT, Grace E, Shenin M et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology 2009;48:1595-9.
19. Herrick AL, Lunt M, Whidby N et al. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 2010;37:116-24.
20. Le EN, Wigely FM, Shah AA et al. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011;70:1104-7.
21. Nihtyanova SI, Brough GM, Black CM et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology 2007; 46:442-5.
22. Koutroumpas A, Ziogas A, Alexiou L et al. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010;29:1167-8.
23. Liossis SNC, Bounas A, Anonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006;45: 1005-8.
24. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008;133:455-60.
25. Zamora AC, Wolters PJ, Collard HR et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008;102:150-5.
26. Swigris JJ, Olson AL, Fischer A et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006;130:30-6.
27. Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 2011;30:1393-8.
28. Henes JC, Horger M, Amberger C et al. Enteric-coated mycophenolate sodium for progressive systemic sclerosis-a prospective open-label study with CT histography for monitoring of pulmonary fibrosis. Clin Rheumatol 2013;32:673-8.
29. Dheda K, Laloo UG, Cassim B et al. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004;23:306-9.
30. Mass D, Schramm A, Jaeckle B et al. Progressive systemic sclerosis-long-term treatment with azathioprine. Immun Infekt 1979;7:165-9.
31. Paone C, Chiarolanza I, Cuomo G et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 2007;25:613-6.
32. Clements PJ, Lachenbruch PA, Sterz M et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993;36:75-83.
33. Filaci G, Cutolo M, Scudeletti M et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology 1999;38:992-6.
34. Morton SJ, Powell RJ. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology 2000;39:865-9.
35. Su TI, Khanna D, Furst DE et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum 2009;60:3821-30.
36. Pham PT, Pham PC, Danovitch GM et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004;77:1215-20.
37. Garrean S, Massad MG, Tashibaka M et al. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 2005;19: 698-703.
38. Matteson EL, Sheeb MI, McCarthy TG et al. Pilot study of antithymocyte globulin in systemic sclerosis. Arthritis Rheum 1996;39:1132-7.
39. Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology 2001; 40:84-8.
40. Durant S, Duval D, Homo-Delarche F. Factors involved in the control of fibroblast proliferation by glucocorticoids: a review. Endocr Rev 1986;7:254-69.
41. Griffiths B, Miles S, Moss H et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002;29: 2371-8.
42. Yiannopoulos G, Pastromas V, Antonopoulos I et al. Combination of intravenous pulses of cyclophosphamide and methylprednisolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 2007; 27:357-61.
43. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-9.
44. Teixeira L, Mouthon L, Mahr A et al. Scleroderma renal crisis: presentation, outcome and risk factors based on retrospective multicenter study of 50 patients. Ann Rheum Dis 2006;54(Suppl):S743.
45. DeMarco PJ, Weisman MH, Seibold JR et al. Predictors and outcomes of scleroderma renal crisis: the high dose versus low dose of penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2983-9.
46. Helfrich DJ, Banner B, Steen VD et al. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989;32: 1128-34.
47. Denton CP, Lapadula G, Mouthon L et al. Renal complications and scleroderma renal crisis. Rheumatology 2009;48(Suppl):iii32-5.
48. Bosello S, De Santis M, Lama G et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010; 12:R50.
49. Smith V, Van Praet JT, Vandooren B et al. Rituximab in diffuse cutaneous systemic sclerosis: an open label clinical and histopathological study. Ann Rheum Dis 2010;69: 193-7.
50. Layaftis R, Kissin E, York M et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009;60:578-83.
51. Daoussis D, Liossis SN, Tsamandas AC et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2010;49:271-80.
52. Daoussis D, Liossis SN, Tsamandas AC et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012;30:17-22.
53. Oliver AM, Clair EWS. Rheumatoid arthritis. Treatment and assessment. In: Klippel JH, ed. Primer on the rheumatic diseases. New York: Springer, 2008:139.
54. Elhai M, Meunier M, Matucci-Cerinic M et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013;72: 1217-20.
55. White B, Choi J, Wigley F et al. Selective T-cell reduction in scleroderma lung disease using LFA-3/IgG1 human fusion protein (alefacept). Arthritis Rheum 2002;46:202.
56. Becker MO, Brückner C, Scherer HU et al. The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open label study. Ann Rheum Dis 2011;70:1340-1.
57. Mauviel A, Daireaux M, Rédini F et al. Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts. FEBS Lett 1988;236:47-52.
58. Mauviel A, Heino J, Kähäri VM et al. Comparative effects of interleukin-1 and tumor necrosis factor-a on collagen production and corresponding procollagen mRNA levels in human dermal fibroblasts. J Invest Dermatol 1991;96: 243-9.
59. Dayer JM, Beutler B, Cerami AJ. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. Exp Med 1985;162:2163-8.
60. Meikle MC, Atkinson SJ, Ward RV et al. Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: evidence that breakdown is mediated by metalloproteinases. J Periodontal Res 1989;24:207-13.
61. Piguet PF, Collart MA, Grau GE et al. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 1990;344:245-7.
62. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994;7:515-8.
63. Lam GK, Hummers LK, Woods A et al. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007;34:1636-7.
64. Ellman MH, MacDonald PA, Hayes FA. Etanercept as treatment for diffuse scleroderma. A pilot study [abstract]. Arthritis Rheum 2000;43(Suppl):392.
65. Denton CP, Engelhart M, Tvede N et al. An open label pilot study of infliximab in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009;68:1433-9.
66. Bosello S, De Santis M, Tolusso B et al. Tumor necrosis factor-a inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med 2005; 143:918-20.
67. Distler JH, Jordan S, Airo P et al. Is there a role for TNFa antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol 2011;29:40-5.
68. Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systemic review. J Rheumatol 2011; 38:289-96.
69. Omair MA, Phumethum V, Johnson SR. Long-term safety and effectiveness of tumor necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis. Clin Exp Rheumatol 2012;30(Suppl 71):55-9.
70. Hasegawa M, Sato S, Fujimoto M et al. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998;25:308-13.
71. Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011;2011:721608. doi: 10.1155/2011/721608.
72. Feghali CA, Bost KL, Boulware DW et al. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992;19: 1207-11.
73. Shima Y, Kuwahara Y, Murota H et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL6 receptor antibody tocilizumab. Rheumatology 2010;49:2408-12.
74. Isaacs JD, Hazleman BL, Chakravarty K et al. Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. J Rheumatol 1996;23:1103-6.
75. McSweeney PA, Nash RA, Sullivan KM et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002;100:1602-10.
76. Hügle T, van Laar JM. Stem cell transplantation for rheumatic autoimmune diseases. Arthritis Res Ther 2008; 10:217.
77. Tyndall A, Matucci-Cerinic M. Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders. Expert Opin Biol Ther 2003; 3:1041-9.
78. Binks M, Passweg JR, Furst D et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001;60:577-84.
79. Farge D, Passweg J, van Laar JM et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004;63:974-81.
80. Nash RA, McSweeney PA, Crofford LJ et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007;110:1388-96.
81. van Laar JM, Farge D, Sont JK et al. The ASTIS trial: autologous stem cell transplantation versus IV pulse cyclophosphamide in poor prognosis systemic sclerosis, first results [abstract]. Ann Rheum Dis 2012; 71(Suppl 3):151.
82. Elhai M, Meune C, Avouac J et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2012;51:1017-26.
83. Goh NS, Desai SR, Veeraraghavan S et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-54.
84. Nagy Z, Czirják L. Predictors of survival in 171 patients with systemic sclerosis (scleroderma). Clin Rheumatol 1997;16:454-60.
85. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991;20:194-208.
86. Furst DE, Clements PJ. Immunosuppressives. In: Klippel JH, Dieppe PA, eds. Rheumatology. 2nd edn. London: Mosby, 1998:9.1-9.10.
87. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 79:723-31.
88. Weinblatt ME. Methotrexate. In: Ruddy S, Harris ED Jr, Sledge CB, eds. Kelley's textbook of rheumatology. 6th edn. Philadelphia: W.B. Saunders, 2001:841-50.
89. Sawitzke AD, Canon GW. Immunomodulatory agents. In: Koopman WJ, Moreland LW, eds. Arthritis and allied conditions. 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2005:885-913.
90. Pisoni CN, D'Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf 2008;7: 219-22.
91. Stein CM. Immunoregulatory drugs. In: Ruddy S, Harris ED Jr, Sledge CB, eds. Kelley's textbook of rheumatology. 6th edn. Philadelphia: W.B. Saunders, 2001:884-6.
92. Airò P, Danieli E, Rossi M et al. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 2007;25:293-6.
93. Beretta L, Caronni M, Raimondi M et al. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol 2007;26: 168-72.
94. Davas EM, Peppas C, Maragou M et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999;18:455-61.
95. Silver RM, Warrick JH, Kinsella MB et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20: 838-44.
96. Espinosa G, Simeón CP, Plasín MÁ et al. Efficacy of cyclophosphamide in the treatment of interstitial lung disease associated with systemic sclerosis. Arch Bronconeumol 2011;47:239-45.